Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genzyme, a Sanofi company, and Veracyte, a molecular diagnostics company, have announced the availability of Afirma Thyroid FNA Analysis across the US.
Subscribe to our email newsletter
The Afirma Thyroid FNA Analysis combines cytopathology assessment of thyroid nodule fine needle aspiration (FNA) samples with the Afirma Gene Expression Classifier for improved thyroid nodule diagnosis.
The Afirma Gene Expression Classifier was shown to reclassify patients with indeterminate thyroid FNA results as benign with the same degree of accuracy as a benign cytopathology diagnosis, in two independent clinical studies.
Genzyme VP and endocrinology GM Alicia Secor said that the combined offering represents a complete personalized solution that advances thyroid nodule assessment and the value of Thyrogen in the management of patients diagnosed with thyroid cancer.
"We expect many patients with thyroid nodules will want to ask their physicians about the Afirma Thyroid FNA Analysis at the beginning of the diagnostic process," Secor added.